Sensex Today Rallies 1,484 Points; Nifty Above 24,400

Asian markets were mostly trading higher on Thursday, tracking strong gains on Wall Street after Democrats recorded a sweeping victory over Republicans in the US midterm elections.

US stock futures were little changed on Thursday after major Wall Street indices posted strong gains in the previous session. The Democratic sweep in the US midterm elections triggered a sharp decline in oil prices amid growing hopes of an end to the Middle East conflict.

Here's a table showing how US stocks performed on Wednesday:

Source: Equitymaster

At present, the BSE Sensex is trading 1,484 points higher, and NSE Nifty is trading 439 points higher.

Bajaj Finance, Asian Paints, Maruti Suzuki are the top gainers today.

Bharti Airtel, NTPC, ITC on the other hand is among the top losers today.

The BSE 150 Midcap index is trading 1.7% higher and the BSE 250 SmallCap index is trading 1.5% higher.

Sectoral indices are trading on a mixed note today, with stocks in the telecommunication sector and power sector witnessed selling pressure. Meanwhile, stocks in realty sector and auto sector witnessed buying interest.

The rupee is trading at Rs 95.2 against the US dollar.

Apollo Hospitals Enterprise Q2 FY27 Results

Leading hospital chain Apollo Hospitals Enterprises (AHEL) reported a 32% rise in consolidated net profit to Rs 6.30 billion (bn) in the second quarter of 2026-27 (Q2FY27), compared to Rs 4.77 bn in the corresponding period of the previous financial year.

Consolidated revenue increased 23% to Rs 76.15 bn from Rs 61.89 bn in Q2FY26. Consolidated earnings before interest, taxes, depreciation and amortisation (Ebitda) grew 29% to Rs 11.91 bn, compared to Rs 9.24 bn in the year-ago quarter.

The company reported strong performance across all three segments, with hospitals recording growth in specialities such as cardiac, oncology, gastroenterology and orthopaedics. International patient volumes increased 37%, supported by a rebound in patients from Bangladesh and strong inflows from Africa and Europe, according to Krishnan Akhileswaran, chief financial officer, AHEL.

Apollo's healthcare services revenue grew 23% year-on-year (Y-o-Y) to Rs 39 bn in Q2FY27 from Rs 31.69 bn a year earlier. Ebitda increased 20% to Rs 9.37 bn from Rs 7.80 bn in Q2FY26, while net profit rose 19% to Rs 4.86 bn from Rs 4.08 bn.

The company's founder and chairman, Prathap C Reddy, attributed the quarterly performance to revenue growth supported by a robust increase in volumes across speciality services. He also highlighted the progress made across the group's businesses and the contribution of its hospitals. Diluted earnings per share from continuing operations stood at Rs 43.71 in Q2FY27.

Overall hospital occupancy stood at 73% in Q2FY27, while occupancy at established units was 76%. Healthcare services EBITDA increased 20% to Rs 9.37 bn during the quarter.

Apollo Health and Lifestyle Ltd (AHLL), the company's diagnostics and retail business, reported 20% Y-o-Y revenue growth in Q2FY27. The diagnostics business recorded a 24% Y-o-Y increase in revenue.

Under the HealthCo segment, the company added 222 stores during the quarter, taking the total store count to 222. Gross merchandise value (GMV) increased 27% to Rs 5.71 bn in Q2FY27 from Rs 4.50 bn in Q2FY26.

Lenskart Q2 FY27 Results

Lenskart Solutions Limited reported a 32.5% year-on-year growth in revenue to Rs 28.45 bn for the quarter ended September 30, 2026, compared with Rs 21.47 bn in the corresponding quarter last year. Profit after tax more than doubled to Rs 2.32 bn from Rs 1.13 bn, supported by higher eyewear sales, increasing demand for premium products and strong performance across domestic and international markets.

EBITDA increased 65.0% year-on-year to Rs 3.92 bn from Rs 2.37 bn. EBITDA margin expanded to 13.8% from 11.1%, reflecting improved operational efficiency and economies of scale. The company's integrated business model, covering brands, manufacturing and distribution, also contributed to the improvement.

For H1FY27, revenue rose 33.0% to Rs 55.59 bn, while profit after tax stood at Rs 4.61 bn, equivalent to 87% of its full-year FY26 profit. Revenue for the trailing 12 months crossed Rs 100 bn.

Peyush Bansal, chairman, managing director and CEO of Lenskart, highlighted the importance of vision correction in improving access to education and opportunities, noting that a significant portion of the global population continues to lack access to corrective eyewear.

India's revenue grew 35.3% year-on-year to Rs 16.68 bn, driven by 26.5% growth in eyewear volumes and rising demand for premium lenses. The company maintained its consolidated product margin at 70.0%, compared with 69.2% in the year-ago period, despite continued depreciation of the rupee.

In-house frame manufacturing recorded 71.7% year-on-year growth, while lens manufacturing increased 52.2%. Higher in-house production helped mitigate currency-related cost pressures while strengthening control over product quality and costs.

International revenue increased 29.5% year-on-year to Rs 12.01 bn, supported by strong growth across Japan, Southeast Asia, the Middle East and other markets. Revenue growth stood at approximately 23% on a constant-currency basis, while eyewear volumes rose 29.7%.